Sotiris Kotsiantis, Georgia Melagraki, Vassilios Verykios, Aikaterini Sakagianni, John Matsoukas
{"title":"Semi-Supervised Learning for Predicting Multiple Sclerosis.","authors":"Sotiris Kotsiantis, Georgia Melagraki, Vassilios Verykios, Aikaterini Sakagianni, John Matsoukas","doi":"10.3390/jpm15050167","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background</b>: Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system with a propensity to inflict severe neurological disability. Accurate and early prediction of MS progression is extremely crucial for its management and treatment. <b>Methods</b>: In this paper, we compare a number of self-labeled semi-supervised learning methods used to predict MS from labeled and unlabeled medical data. Specifically, we compare the performance of Self-Training, SETRED, Co-Training, Co-Training by Committee, Democratic Co-Learning, RASCO, RelRASCO, CoForest, and TriTraining in different labeled ratios. The data contain clinical, imaging, and demographic features, allowing for a detailed comparison of each method's predictive ability. <b>Results and Conclusions</b>: The experimental results demonstrate that several self-labeling semi-supervised learning (SSL) algorithms perform competitively in the task of Multiple Sclerosis (MS) prediction, even when trained on as little as 30-40% of the labeled data. Notably, Co-Training by Committee, CoForest, and TriTraining consistently deliver high performance across all metrics (accuracy, F1-score, and MCC).</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 5","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12113346/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm15050167","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system with a propensity to inflict severe neurological disability. Accurate and early prediction of MS progression is extremely crucial for its management and treatment. Methods: In this paper, we compare a number of self-labeled semi-supervised learning methods used to predict MS from labeled and unlabeled medical data. Specifically, we compare the performance of Self-Training, SETRED, Co-Training, Co-Training by Committee, Democratic Co-Learning, RASCO, RelRASCO, CoForest, and TriTraining in different labeled ratios. The data contain clinical, imaging, and demographic features, allowing for a detailed comparison of each method's predictive ability. Results and Conclusions: The experimental results demonstrate that several self-labeling semi-supervised learning (SSL) algorithms perform competitively in the task of Multiple Sclerosis (MS) prediction, even when trained on as little as 30-40% of the labeled data. Notably, Co-Training by Committee, CoForest, and TriTraining consistently deliver high performance across all metrics (accuracy, F1-score, and MCC).
背景:多发性硬化症(MS)是一种慢性自身免疫性疾病的中枢神经系统与倾向造成严重的神经功能障碍。准确和早期预测多发性硬化症的进展对其管理和治疗至关重要。方法:在本文中,我们比较了一些用于从标记和未标记的医疗数据中预测MS的自标记半监督学习方法。具体来说,我们比较了Self-Training、SETRED、Co-Training、Co-Training by Committee、Democratic Co-Learning、RASCO、RelRASCO、CoForest和trittraining在不同标记比率下的表现。数据包含临床、影像和人口特征,允许对每种方法的预测能力进行详细的比较。结果和结论:实验结果表明,几种自标记半监督学习(SSL)算法在多发性硬化症(MS)预测任务中表现出竞争力,即使在只有30-40%的标记数据上进行训练。值得注意的是,由Committee、CoForest和trittraining共同进行的培训始终如一地在所有指标(准确性、f1分数和MCC)上提供高性能。
期刊介绍:
Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.